Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00899847
Other study ID # IRB-15772
Secondary ID SU-04142009-2259
Status Completed
Phase Phase 2
First received May 8, 2009
Last updated September 19, 2017
Start date May 2009
Est. completion date December 2014

Study information

Verified date September 2017
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant approach for patients with advanced stage multiple myeloma.


Description:

Development of cell-based immunotherapy from allogeneic hematopoietic cell transplantation (HCT) is dependent upon stable T-cell engraftment and the success of this therapeutic approach is likely to be greatest when directed against a minimal rather than gross tumor burden. To this end, tandem transplants with high dose therapy and autologous hematopoietic cell transplantation (AHCT) for tumor cytoreduction followed by non-myeloablative allotransplant have been conducted. In myeloma, this tandem approach results in greater efficacy compared to conventional AHCT.


Recruitment information / eligibility

Status Completed
Enrollment 9
Est. completion date December 2014
Est. primary completion date April 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility PARTICIPANT INCLUSION CRITERIA

- Stage II-III multiple myeloma or have progression after initial treatment of Stage I disease (Durie Salmon Staging). Patients with plasma cell leukemia are also included.

- Multiple myeloma / plasma cell leukemia diagnosis confirmed by pathology reviewed at Stanford University Medical Center.

- 18 to = 75 years of age

- Karnofsky Performance Status > 70%.

- Corrected Carbon monoxide diffusing capacity (Dlco) > 60%

- Left ventricle ejection fraction (LVEF) > 50%.

- Alanine aminotransferase (ALT) = 2 x normal

- Aspartate aminotransferase (AST) = 2 x normal

- Total bilirubin = 2 mg/dL, unless hemolysis or Gilbert's disease.

- Estimated creatinine clearance > 50 mL/min.

- Identified related or unrelated Human leukocyte antigen (HLA)-identical donor or donor with one antigen/allele mismatch in (HLA-A, B, C or DRB1).

- Signed informed consent.

DONOR INCLUSION CRITERIA

- At least 17 years of age

- HIV-seronegative

- Must be capable of giving signed, informed consent

- No contraindication to the administration of filgrastim

- Willing to have a central venous catheter placed for apheresis if peripheral veins are inadequate

PARTICIPANT EXCLUSION CRITERIA

- Prior allogeneic hematopoietic cell transplantation

- Uncontrolled active infection

- Uncontrolled congestive heart failure or angina

- HIV-positive

- Pregnant or nursing

DONOR EXCLUSION CRITERIA

- Serious medical or psychological illness

- Pregnant or lactating

- Prior malignancies within the last 5 years except for non-melanoma skin cancers

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Autologous peripheral blood stem cells (auto-PBSC) transplantation
Auto-PBSC = 2 to 3 x 10e6 CD34+ cells/kg are intravenously (IV) infused as part of the combination stem cell therapy. and allogeneic stem cells are administered intravenous (IV) infusion to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective
Allogeneic peripheral blood stem cells (allo-PBSC) transplantation
Allo-PBSC (target collection = 5 x 10e6 CD34+ cells/kg) are intravenously (IV) infused as part of the combination stem cell therapy.
Drug:
Filgrastim
Filgrastim is administered subcutaneously (SC) at 10 µg/kg/day for auto-PBSC mobilization starting day 2 of mobilization until the last day of apheresis. Filgrastim is administered SC at 5 µg/kg/day from Day 6 after auto-PBSC infusion to hematologic recovery. Filgrastim is administered SC at 16 µg/kg/day for donor allo-PBSC mobilization at from Day - 4 to Day 0, prior to allo-PBSC collection.
Cyclophosphamide
Cyclophosphamide is administered intravenously (IV) at 4 g/m2 on Day 1 of the auto-PBSC mobilization regimen.
Melphalan
Melphalan is administered after CSP at 200 mg/m2 intravenously (IV) on Day -2 before auto-PBSC infusion.
Cyclosporine
Cyclosporine is administered by mouth (PO) for allo-PBSC graft vs host disease (GvHD) prophylaxis at 5 mg/kg from Day -3 through Bay +56. Tacrolimus may substituted.
Radiation:
Total lymphoid irradiation
Total lymphoid irradiation is administered at 80 centigrey (cGy) on Day -11 to -7; and Day -4 to -2 before alllo-PBSC infusion. TLI is also administered at 80 centigrey (cGy) x 2 on Day -1 before alllo-PBSC infusion.
Biological:
Rabbit anti-thymocyte globulin
ATG 1.5 mg/kg is administered intravenously (IV) on Day -11 to -7 before allo-PBSC infusion.
Drug:
Mycophenolate Mofetil 250mg
MMF is administered at 15 mg/kg 3x/day by mouth (PO) after allo-PBSC through Day 40, followed by 10% dose reduction weekly (dose taper) through day 96, and adjusted if there is evidence of MMF-related GI toxicity or excessive myelosuppression
Solumedrol
Solumedrol 1 mg/kg is administered intravenously (IV) on Day -11 to -7 as a premedication for ATG and allo-PBSC infusion
Diphenhydramine
Diphenhydramine 25 to 50 mg is administered as a premedication for the ATG; allo-PBSC; and DLI infusions.
Acetaminophen
Acetaminophen 650 mg is administered as a premedication for the ATG and allo-PBSC infusions.
Hydrocortisone
Hydrocortisone 100 mg is administered intravenously (IV) is a premedication for the allo-PBSC and DLI infusions.

Locations

Country Name City State
United States Stanford University School of Medicine Stanford California

Sponsors (1)

Lead Sponsor Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Graft Versus Host Disease (GvHD) To evaluate the incidence acute GvHD of this tandem autologous/allogeneic transplant setting 2 years after the last participant is enrolled.
Secondary Median Time to Engraftment After Auto-PBSC Transplant Engraftment is assessed as:
Neutrophil engraftment is > 0.5 x 10?/L after cytopenia
Platelet engraftment is > 20 x 10?/L after cytopenia
1 month
Secondary Median Time to Engraftment After Allo-PBSC Transplant Engraftment is assessed as:
Neutrophil engraftment is > 0.5 x 10?/L after cytopenia
Platelet engraftment is > 20 x 10?/L after cytopenia
1 month
Secondary Overall Response Rate (ORR) Overall response rate (ORR) = Complete Response Rate (CRR) + Partial Response Rate (PRR) 1 year
Secondary Complete Response Rate (CRR) Complete response rate (CRR) was assessed as all of:
Negative immunoflixation on the serum and urine
Disappearance of any soft tissue plasmacytomas
< 5% plasma cells in bone marrow
1 year
Secondary Partial Response Rate (PRR) Partial response rate (PRR) was assessed as
> 50% reduction in serum M-protein plus urine M-protein reduction by 90% or < 200 mg/24 hr
If serum M-protein is not measurable, then > 50% reduction in the involved serum free light chain
If involved serum free light chain is not measurable, then > 50% reduction in the bone marrow plasma cell percentage + > 50% reduction in the size of any soft tissue plasmacytoma.
1 year
Secondary Event-free Survival (EFS) To evaluate the graft versus myeloma effect by monitoring rate of event-free survival (EFS) 2 years after the last participant is enrolled
Secondary Overall Survival (OS) To evaluate the graft versus myeloma effect by monitoring rate of overall survival (OS) 2 years after the last participant is enrolled
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1